Cullman, AL

North Central Neurology

Relapsing-Remitting Multiple Sclerosis

Sclerosis

Multiple Sclerosis

ANK-700

Anokion

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:

Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

North Central Neurology | Cullman, AL

Site insights

Work at this site?

Active trials

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)

Trial sponsors